| dc.contributor.author |
Kokotos, G |
en |
| dc.contributor.author |
Constantinou-Kokotou, V |
en |
| dc.contributor.author |
Padron, JM |
en |
| dc.contributor.author |
Peters, GJ |
en |
| dc.date.accessioned |
2014-06-06T06:44:43Z |
|
| dc.date.available |
2014-06-06T06:44:43Z |
|
| dc.date.issued |
2001 |
en |
| dc.identifier.issn |
0960894X |
en |
| dc.identifier.uri |
http://dx.doi.org/10.1016/S0960-894X(01)00084-1 |
en |
| dc.identifier.uri |
http://62.217.125.90/xmlui/handle/123456789/2029 |
|
| dc.subject.other |
2 tetradecylbutane 1,4 diol dimethanesulfonate |
en |
| dc.subject.other |
busulfan |
en |
| dc.subject.other |
sulfonic acid derivative |
en |
| dc.subject.other |
unclassified drug |
en |
| dc.subject.other |
animal cell |
en |
| dc.subject.other |
article |
en |
| dc.subject.other |
controlled study |
en |
| dc.subject.other |
drug activity |
en |
| dc.subject.other |
drug cytotoxicity |
en |
| dc.subject.other |
drug synthesis |
en |
| dc.subject.other |
human |
en |
| dc.subject.other |
human cell |
en |
| dc.subject.other |
in vitro study |
en |
| dc.subject.other |
nonhuman |
en |
| dc.subject.other |
tumor cell line |
en |
| dc.subject.other |
Alkanes |
en |
| dc.subject.other |
Animals |
en |
| dc.subject.other |
Antineoplastic Agents |
en |
| dc.subject.other |
Busulfan |
en |
| dc.subject.other |
Cell Division |
en |
| dc.subject.other |
Inhibitory Concentration 50 |
en |
| dc.subject.other |
Mesylates |
en |
| dc.subject.other |
Tumor Cells, Cultured |
en |
| dc.title |
Synthesis and in vitro cytotoxicity of novel long chain busulphan analogues |
en |
| heal.type |
journalArticle |
en |
| heal.identifier.primary |
10.1016/S0960-894X(01)00084-1 |
en |
| heal.publicationDate |
2001 |
en |
| heal.abstract |
Two novel long chain alkanediol dimethanesulphonates, analogues of busulphan, were synthesized. Their in vitro cytotoxicity was evaluated against six solid tumor cell lines (A2780, H322, LL, WiDr, C26-10 and UMSCC-22B). 2-Tetradecylbutane-1,4-diol dimethanesulphonate was proved to be the most active compound exhibiting IC50 values between 20.82 and 26.36 μM. © 2001 Elsevier Science Ltd. |
en |
| heal.journalName |
Bioorganic and Medicinal Chemistry Letters |
en |
| dc.identifier.issue |
6 |
en |
| dc.identifier.volume |
11 |
en |
| dc.identifier.doi |
10.1016/S0960-894X(01)00084-1 |
en |
| dc.identifier.spage |
861 |
en |
| dc.identifier.epage |
863 |
en |